APP gets OK for chemo drug
SCHAUMBURG - APP Pharmaceuticals, Inc., a subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc., announced Monday that it has received approval from the U.S. Food and Drug Administration to market idarubicin hydrochloride injection, the foundation of many chemotherapy regimens and for use as a therapy in patients with acute myeloid leukemia. Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by Pfizer Inc. APP expects to launch the drug in September.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.